4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,909 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total value of $57,270.00. Following the sale, the insider now owns 1,737 shares in the company, valued at […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $22.57, for a total value of $4,164,187.57. Following the transaction, the insider now directly owns […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason P. Rhodes sold 177,906 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $23.89, for a total transaction of $4,250,174.34. Following the completion of the transaction, the director now owns 7,148,211 shares in […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason P. Rhodes sold 169,539 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $22.72, for a total transaction of $3,851,926.08. Following the transaction, the director now owns 6,815,965 shares of the […]
Silverarc Capital Management LLC raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,438 shares of the company’s stock after purchasing an additional 2,438 shares during […]